🔍 It highlights how various factors, like media composition and processing parameters, influence HCP levels.
💡 Research by Merck’s team shows that viability is not a reliable HCP indicator.
🔄 Instead, controlling these factors can significantly reduce HCPs, leading to more effective therapies.
Introduction:
This article discusses the challenges associated with minimizing host cell protein (HCP) levels in monoclonal antibody therapies produced using Chinese Hamster Ovary (CHO) cells. It outlines a study conducted by researchers at Merck that offers a new perspective on the multiple factors influencing HCP levels, suggesting that traditional metrics such as cell viability may not be adequate in this context.
- Monoclonal antibody therapies rely on CHO cells, which also produce HCPs that can negatively impact drug efficacy and patient safety.
- Manufacturers commonly use cell viability as a proxy for HCP levels, but evidence suggests this metric alone is unreliable.
- The research team employed transcriptomics to analyze HCPs produced in CHO cultures and sought upstream interventions.
- HCP concentrations are influenced by various bioprocess parameters, including culture media, temperature, and dissolved oxygen levels.
- The findings reveal that factors such as clone selection and host cell line characteristics are significant for controlling HCP levels, challenging the traditional reliance on viability metrics.
Conclusion:
This study underscores the complexity of HCP management in CHO-based therapeutics, indicating that a multifaceted approach is necessary for effective control. By understanding and manipulating the diverse factors involved, manufacturers can better optimize the production processes, potentially enhancing the safety and efficacy of monoclonal antibody therapies in future bioprocessing applications.
